傲農生物(603363.SH):生豬養殖已經從上量階段轉向穩定經營階段,目前暫緩新的擴張
格隆匯5月15日丨有投資者在投資者互動平台向傲農生物(603363.SH)提問,“請問貴公司二季度存貨計提是多少?當前養殖户內耗嚴重,拼家底,公司如何應對行業困局?”
傲農生物回覆稱,1、公司生豬養殖已經從上量階段轉向穩定經營階段,目前暫緩新的擴張,繼續強化降本增效的措施;2、發揮穩定增長的飼料、屠宰食品業務收入佔比較大的特點,繼續提升非養殖業務收入規模,增加流動性盤子,同時增加該等業務的利潤貢獻;3、完善和優化供應鏈、金融機構合作等;4、繼續加快推進再融資事項,促進持續穩定發展。接下來“降成本、降負債”將成為公司的核心工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.